Details for Patent: 7,951,400
✉ Email this page to a colleague
Which drugs does patent 7,951,400 protect, and when does it expire?
Patent 7,951,400 protects ONGLYZA and is included in one NDA.
This patent has fifty-seven patent family members in thirty-two countries.
Summary for Patent: 7,951,400
| Title: | Coated tablet formulation and method |
| Abstract: | A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin ##STR00001## or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided. |
| Inventor(s): | Desai; Divyakant S. (West Windsor, NJ), Li; Bing V. (Germantown, MD) |
| Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
| Application Number: | 11/137,068 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,951,400 |
|
Patent Claim Types: see list of patent claims | Formulation; Compound; Dosage form; Composition; |
Drugs Protected by US Patent 7,951,400
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | ONGLYZA | saxagliptin hydrochloride | TABLET;ORAL | 022350-001 | Jul 31, 2009 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Astrazeneca Ab | ONGLYZA | saxagliptin hydrochloride | TABLET;ORAL | 022350-002 | Jul 31, 2009 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,951,400
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 049062 | ⤷ Sign Up | |||
| Argentina | 099567 | ⤷ Sign Up | |||
| Australia | 2005249467 | ⤷ Sign Up | |||
| Brazil | PI0510419 | ⤷ Sign Up | |||
| Canada | 2568391 | ⤷ Sign Up | |||
| China | 102895208 | ⤷ Sign Up | |||
| China | 1988891 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
